Invesco
FDMT icon

Invesco’s 4D Molecular Therapeutics FDMT Stock Holding History

Invesco’s Portfolio FDMT Stock Details FDMT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2M Sell
150,382
-160,302
-52% -$1.56M ﹤0.01% 2590
2026
Q1 		$2.89M Buy
310,684
+157,542
+103% +$1.37M ﹤0.01% 2393
2025
Q4 		$1.15M Buy
153,142
+26,563
+21% +$269K ﹤0.01% 2852
2025
Q3 		$1.1M Sell
126,579
-13,746
-10% -$82.2K ﹤0.01% 2882
2025
Q2 		$521K Buy
140,325
+22,557
+19% +$79.3K ﹤0.01% 3139
2025
Q1 		$380K Buy
117,768
+89,611
+318% +$422K ﹤0.01% 3265
2024
Q4 		$157K Buy
28,157
+732
+3% +$5.74K ﹤0.01% 3556
2024
Q3 		$296K Sell
27,425
-27
-0.1% -$448 ﹤0.01% 3419
2024
Q2 		$576K Sell
27,452
-217
-0.8% -$5.44K ﹤0.01% 3217
2024
Q1 		$882K Buy
27,669
+13,591
+97% +$347K ﹤0.01% 3054
2023
Q4 		$285K Sell
14,078
-3,398
-19% -$44.7K ﹤0.01% 3451
2023
Q3 		$222K Sell
17,476
-198,100
-92% -$3.31M ﹤0.01% 3552
2023
Q2 		$3.9M Buy
+215,576
New +$3.97M ﹤0.01% 2361
2023
Q1 		– Sell
-196,201
Closed -$4.36M – 3911
2022
Q4 		$4.36M Buy
196,201
+185,652
+1,760% +$2.87M ﹤0.01% 2320
2022
Q3 		$85K Sell
10,549
-104
-1% -$942 ﹤0.01% 3861
2022
Q2 		$75K Sell
10,653
-92
-0.9% -$894 ﹤0.01% 3933
2022
Q1 		$163K Sell
10,745
-235
-2% -$3.69K ﹤0.01% 3804
2021
Q4 		$241K Buy
+10,980
New +$269K ﹤0.01% 3709

Other funds holding FDMT

JT
Jupiter Topco New York $245B AUM
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.72B AUM 106.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
TECP
Trails Edge Capital Partners Atlanta, Georgia $630M AUM

Invesco's FDMT Position: Q2 2026 in Review

Invesco reduced its 4D Molecular Therapeutics (FDMT) stake by 52% in Q2 2026, selling an estimated $1.56M and leaving 150,382 shares worth $2M. The position accounts for ﹤0.01% of the portfolio, ranked #2590.

Invesco first reported a position in FDMT in Q4 2021 and has held it in 18 quarters since. The position peaked at $4.36M in Q4 2022. 158 funds tracked by Wall St. Rank hold FDMT as of Q2 2026.

  • Invesco held 150,382 shares of 4D Molecular Therapeutics worth $2M as of Q2 2026.
  • Invesco sold 160,302 4D Molecular Therapeutics shares in Q2 2026, an estimated $1.56M.
  • 4D Molecular Therapeutics made up ﹤0.01% of Invesco's portfolio in Q2 2026, its #2590 holding.
  • Invesco first reported a position in 4D Molecular Therapeutics in Q4 2021 and has held it in 18 quarters since.
  • Invesco's 4D Molecular Therapeutics position peaked at $4.36M in Q4 2022.
  • 158 funds tracked by Wall St. Rank held 4D Molecular Therapeutics as of Q2 2026.

Based on Invesco's 13F filing for Q2 2026, filed 14 Aug 2026.